Altered fibrillar collagen metabolism in hypertensive heart failure. Current understanding and future prospects;Alteraciones del metabolismo del colágeno fibrilar en la cardiopatía hipertensiva. Situación actual y perspectivas

Revista Espanola de Cardiologia

Volumn 59, Issue 10, 2006, Pages 1047-1057

  López Salazar, Begoña ^a   Ravassa Albéniz, Susana ^a   Arias Guedón, Teresa ^a   González Miqueo, Arantxa ^a   Querejeta, Ramón ^b   Díez Martínez, Javier ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Collagen; Fibrosis; Peptides; Systemic arterial hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOSARTAN; TORASEMIDE; TRANILAST;

BIOCHEMISTRY; CLINICAL PROTOCOL; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; DIAGNOSTIC PROCEDURE; HEART; HEART FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; REVIEW;

EID: 37849185302     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093982     Document Type: Review

References (67)

1. Jiménez Navarro MF, Díez Martínez J, Delgado Jiménez JF, Crespo Leiro MG. La insuficiencia cardiaca en 2005. Rev Esp Cardiol. 2006;59 Supl 1:55-65.
2. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998;16:1031-41.
3. Querejeta R, Varo N, López B, Layman M, Artiñano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-35.
4. Olivetti G, Melissari M, Balbi T. Myocyte celullar hypertrophy is responsible for ventricular remodeling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res. 1994;28:1199-208.
5. Weber KT, Sun Y, Dhalla AK, Guntaka RV. Extracellular matrix and fibrosis in cardiac hypertrophy. En: Sheridan DJ, editor. Left ventricular hypertrophy. London: Churchill Livingstone; 1998. p. 37-44.
6. Pardo Mindán FJ, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J. 1993; 14:J12-4.
7. Weber KT. Fibrosis and hypertensive heart disease. Curr Opinion Cardiol. 2000;15:264-72.
8. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens. 1999;17:107-14.
9. Varo N, Iraburu MJ, Varela M, López B, Etayo JC, Díez J. Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 2000;35:1197-202.
10. Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res. 1999;42:27-44.
11. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J. 1986;55:575-81.
12. Amanuma S, Sekiguchi M, Ogasawara S, Honda M, Hosoda S. Biventricular endomyocardial biopsy findings in essential hypertension of graded severity. Postgrad Med J. 1994;70 Suppl 1:S67-71.
13. Pearlman ES, Weber KT, Janicki JS, Pietra GG, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158-64.
14. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90:400-5.
15. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-93.
16. López B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I to assess the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286-91.
17. Schwartzkopff B, Brehm M, Mundhenke M, Strauer B. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000;36:220-5.
18. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512-7.
19. González A, López B, Querejeta R, Díez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol. 2002:34:1585-93.
20. Díez J. Profibrotic effects of angiotensin II in the heart: a matter of mediators. Hypertension. 2004;43:1164-5.
21. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension. 2004;43:499-503.
22. Lijnen P and Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865-79.
23. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effect of spironolactone in preventing myocardial fibrosis in systemic arterial hvnertension. Am J Cardiol. 1993:71:A12-6.
24. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured,adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-20.
25. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828-36.
26. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-7.
27. Challah M, Villard E, Philippe M, Ribadeau-Dumas A, Giraudeau B, Janiak P, et al. Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats. Arterioscler Thromb Vasc Biol. 1998;18:235-43.
28. Ocaranza MP, Diaz-Araya G, Carreno JE, Muñoz D, Riveros JP, Jalil JE, et al. Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats. Am J Physiol Heart Circ Physiol. 2004;286:H498-506.
29. 1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens. 2003;21:2085-92.
30. Varagic J, Frohlich ED, Díez J, Susic D, Ahn J, González A, et al. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. Am J Physiol Heart Circ Physiol. 2006;290:H1503-9.
31. Díez J, López B, González A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol. 2001; 16:328-35.
32. Weber KT. Cardiac interstitium. En: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS, editors. Heart failure. Scientific principles and clinical practice. New York: Churchill Livingstone; 1997. p. 13-31.
33. Weber KT, Brilla CG, Janicki JS. Miocardial fibrosis. Functional significance and regulatory factors. Cardiovasc Res. 1993;27:13-31.
34. Sugihara N, Genda A, Shimizu M, Suematsu T, Kita Y, Minamoto M, et al. Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension. J Cardiol. 1988;18:353-61.
35. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation. 2004;110:1263-8.
36. McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens. 1990;3:735-40.
37. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-35.
38. Houghton JL, Frank MJ, Carr VD, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive artery disease. J Am Coll Cardiol. 1990;15:43-51.
39. Vogt M, Strauer BE. Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Am J Cardiol. 1995;76:D48-53.
40. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993;88:993-1003.
41. Isoyama S, Ito N, Satoh U, Takishima T. Collagen deposition and the reversal of coronary reserve in cardiac hypertrophy. Hypertension. 1992;20:491-500.
42. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;60:560-5.
43. Assayag P, Carré F, Chevalier B, Delcayre C, Mansier P, Swynghedouw B. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res. 1997; 34:439-44.
44. Davidson CJ, Bonow RO. Cardiac catheterization. En: Braunwald E, Zipes DP, Libby P, editors. Heart disease. A textbook of cardiovascular medicine. 6th ed. Philadelphia: WB Saunders Company; 2001. p. 359-66.
45. Kerut EK, Given M, Giles TD. Review of methods for texture analysis of myocardium from echocardiographic images: a means of tissue characterization. Echocardiography. 2003;20:727-30.
46. Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F, et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr. 1997;10:657-64.
47. Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L, et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation. 1990;81:58-64.
48. Tandri H, Saranathan M, Rodríguez ER, Martinez C, Bomma C, Nasir K, et al. Non invasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomypathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98-103.
49. Estornell J, Lṕez MP, Dicenta F, Igual B, Martínez V, Sonlleva A. Utilidad de la resonancia magnética en el estudio de la enfermedad endomiocárdica. Rev Esp Cardiol. 2003;56:321-4.
50. López B, González A, Querejeta R, Díez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens. 2005;23:1445-51.
51. Díez J, Panizo A, Gil MJ, Monreal I, Hernández M, Pardo Mindán J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation. 1996;93:1026-32.
52. López B, González A, Querejeta R, larman M, Díez J. Alterations of the pattern of collagen deposition may contribuye to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006;48:89-96.
53. Jiménez-Navarro MF, Gómez-Doblas JJ, Cabrera-Bueno F, Cruz-Ocaña E, Rodríguez-Bailón I, Ruiz-Galdón M, et al. Síntesis de colágeno e insuficiencia cardiaca. Rev Esp Cardiol. 2005;58:975-8.
54. Guidelines Committee of the European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
55. Weber KT. Targeting pathological remodeling: concepts of cardioprotection and reparation. Circulation. 2000;102:1342-5.
56. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-9.
57. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:45-50.
58. Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido H, Watanabe M. Anti-aldosteronic effect of torasemide. Eur J Pharmacol. 1991;205:145-50.
59. Tsutamoto T, Sakai H, Wada A, Ishikawa C, Ohno K, Fujii M, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2252-3.
60. Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M, Inoue H. Tranilast attenuates myocardial fibrosis en association with supression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens. 2004:22:1007-15.
61. Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sánchez-Maendoza A, et al. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens. 2004;22:593-603.
62. Ogata T, Miyauchi T, Irukayama-Tomobe Y, Takanashi M, Goto K, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferators-activated receptor-alpha activator fenofibrate, partly by supressing inflammatory responses associated with the nuclear factor-kappa-B. J Am Coll Cardiol. 2004;43:1481-8.
63. Meiners S, Hocher B, Weller A, Laule M, Stangl V, Guenther C, et al. Downregulation of matrix metalloproteinases and collagens and supression of cardiac fibrosis by inhibition of the proteasome. Hypertension. 2004;44:471-7.
64. D'Ascia C, Cittadini A, Monti MG, Riccio G, Saccà L. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-α expression, and apoptotic death in failing human myocardium. Eur Heart J. 2006;27:201-6.
65. García-Bolao I, Macías A, López B, González A, Gavira JJ, Azcárate P, et al. A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. J Am Coll Cardiol. 2006;47:2335-7
66. Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V, et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol. 2006;290:H2196-203.
67. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. En prensa 2006.